Niacin and Lipoprotein(a): Facts, Uncertainties, and Clinical Considerations

American Journal of Cardiology

Volumn 101, Issue 8 SUPPL. 1, 2008, Pages

  Scanu, Angelo M ^a   Bamba, Ravi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; ATORVASTATIN; CHOLESTEROL; COLESTIPOL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; NICOTINIC ACID; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CHOLESTEROL METABOLISM; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; GENETIC POLYMORPHISM; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LOW DRUG DOSE; MONOTHERAPY; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN(A); NIACIN; TRIGLYCERIDES;

EID: 41049104847     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.02.031     Document Type: Article

References (26)

1. Guyton J.R. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol 18 (2007) 415-442
2. Sanyal S., Karas R.H., and Kuvin J.T. Present-day uses of niacin: effects on lipid and non-lipid parameters. Expert Opin Pharmacother 8 (2007) 1711-1718
3. Aetschul R., Hoffer A., and Stephen J.D. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 54 (1955) 558-559
4. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
5. Knopp R.H. Evaluating niacin in its various forms. Am J Cardiol 86 suppl (2000) 51L-56L
6. Ganji S.H., Kamanna V.S., and Kashyap M.L. Niacin and cholesterol: role in cardiovascular disease. J Nutr Biochem 14 (2003) 298-305
7. Carlson L.A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 258 (2005) 94-114
8. Carlson L.A., Hamsten A., and Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 226 (1989) 271-276
9. Maher V.M.G., Brown B.G., Marcovina S., Hillger L.A., Zhao X.-Q., and Albers J. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 274 (1995) 1771-1774
10. Morgan J.M., Capuzzi D., and Guyton J.R. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 82 suppl (1998) 29U-34U
11. Capuzzi D., Guyton J.R., Morgan J.M., Goldberg A.C., Kreisberg R.A., Brusco O.A., and Brody J. Efficacy and safety of an extended-release niacin (Niaspan): a long term study. Am J Cardiol 82 (1998) 74U-81U
12. McKenney J.M., Jones P., Bays H., Knopp R., Kashyap M., Ruoff G., and McGovern M. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL [Comparative Effects on Lipid Levels of Niaspan and Statins Versus Other Lipid Therapies] study). Atherosclerosis 192 (2007) 432-437
13. Pan J., Van J.T., Chan E., Kesala R.L., Lin M., and Charles M.A. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes. Metabolism 51 (2002) 1120-1127
14. Pan J., Lin M., Kesala R.L., Van J., and Charles M.A. Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. Diabetes Obes Metab 4 (2002) 255-261
15. Scanu A.M. Lp(a) lipoprotein-coping with heterogeneity. N Engl J Med 349 (2003) 2089-2090
16. Marcovina S.M., Koschinsky M.L., Albers J.J., and Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 49 (2003) 1785-1796
17. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., Gallimore J.R., and Pepys M.B. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 321 (2000) 199-204
18. Hobbs H.H., and White A.L. Lipoprotein(a): intrigues and insights. Curr Opin Lipidol 10 (1999) 225-236
19. Edelstein C., Davidson N.O., and Scanu A.M. Oleate stimulates the formation of the triglyceride-rich particles containing apoB100-apo(a) in long term primary cultures of human hepatocytes. Chem Phys Lipids 67 (1994) 135-143 68
20. Bonen D.K., Hausman A.M.L., Hadjiagapiou C., Skarosi S.F., and Davidson N.O. Expression of a recombinant apolipoprotein(a) in HepG2 cells. J Biol Chem 272 (1997) 5659-5667
21. Nassir F., Bonen D.K., and Davidson N.O. Apolipoprotein(a) synthesis and secretion from hepatoma cells is coupled to triglyceride synthesis and secretion. J Biol Chem 273 (1998) 17793-17800
22. Edelstein C., Pfaffinger D., Hinamn J., Miller E., Lipkind G., Tsimikas S., Bergmark C., Getz G., Witztum J., and Scanu A.M. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 278 (2003) 52841-52847
23. Klezovitch O., Edelstein C., and Scanu A.M. Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein(a): evidence for a critical involvement of elements of its C-terminal domain. J Biol Chem 276 (2001) 46864-46869
24. Tsimikas S., Brilakis E.S., Miller E.R., McConell J.P., Lennon R.J., Kornman K.S., Witztum J.L., and Berger P.B. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 353 (2005) 46-57
25. Atac I.A., Peksel A., Yanardag R., Sokmen B.B., Doger M.M., and Bilen Z.G. The effect of combined treatment with niacin and chromium (III) chloride on the different tissues of hyperlipemic rats. Drug Chem Toxicol 29 (2006) 363-377
26. Kuvin J.T., Dave D.M., Sliney A.S., Mooney P., Patel A.R., Kimmelstiel C.D., and Karas R.H. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary heart disease. Am J Cardiol 98 (2006) 743-745